Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01235819

Enrollment

Registered

2010-11-08

Start date

2010-11-30

Completion date

2011-09-30

Last updated

2016-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

type 1 diabetes, exenatide, sitagliptin

Brief summary

To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.

Detailed description

Inclusion criteria T1DM \<3 months GAD Antibody+ Stimulated C peptide\<0.5ng/ml Ketosis at onset Age \< 30 yr Exclusion criteria Age \> 30 yr Pancreatic disease significant systemic complication

Interventions

DRUGInsulin

Exenatide Sitagliptin

DRUGSitagliptin

Sitagliptin 100 mg per day oral

DRUGExenatide

Exenatide 10 micrograms daily twice

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to 30 Years

Healthy volunteers

Inclusion criteria

* T1DM \<3 months * GAD Antibody+ or Stimulated C peptide\<0.5 ng/ml * Ketosis at onset * Age \< 30 yr

Exclusion criteria

* Age \> 30 yr * Pancreas disease * Significant systemic disease

Design outcomes

Primary

Measure	Time frame	Description
change in insulin requirement	one year	To assess the change in insulin requirement with use of GLP 1 analogues or DPP 4 inhibitors along with insulin in type 1 diabetes

Secondary

Measure	Time frame	Description
C peptide response	at the end of one year	To assess the endogenous insulin secretion after one year of use of GLp 1 analogue and DPP 4 inhibitors

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026